These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34312615)

  • 21. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
    Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
    Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct in vitro and in vivo neutralization profiles of monoclonal antibodies elicited by the receptor binding domain of the ancestral SARS-CoV-2.
    Kwon HJ; Zhang J; Kosikova M; Tang W; Ortega-Rodriguez U; Peng H; Meseda CA; Pedro CL; Schmeisser F; Lu J; Kang I; Zhou B; Davis CT; Wentworth DE; Chen WH; Shriver MC; Barnes RS; Pasetti MF; Weir JP; Chen B; Xie H
    J Med Virol; 2023 Mar; 95(3):e28673. PubMed ID: 36916782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
    Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
    Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD.
    Zhou Y; Liu Z; Li S; Xu W; Zhang Q; Silva IT; Li C; Wu Y; Jiang Q; Liu Z; Wang Q; Guo Y; Wu J; Gu C; Cai X; Qu D; Mayer CT; Wang X; Jiang S; Ying T; Yuan Z; Xie Y; Wen Y; Lu L; Wang Q
    Cell Rep; 2021 Feb; 34(5):108699. PubMed ID: 33485405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants.
    Vanhove B; Marot S; So RT; Gaborit B; Evanno G; Malet I; Lafrogne G; Mevel E; Ciron C; Royer PJ; Lheriteau E; Raffi F; Bruzzone R; Mok CKP; Duvaux O; Marcelin AG; Calvez V
    Front Immunol; 2021; 12():761250. PubMed ID: 34868003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope.
    VanBlargan LA; Adams LJ; Liu Z; Chen RE; Gilchuk P; Raju S; Smith BK; Zhao H; Case JB; Winkler ES; Whitener BM; Droit L; Aziati ID; Bricker TL; Joshi A; Shi PY; Creanga A; Pegu A; Handley SA; Wang D; Boon ACM; Crowe JE; Whelan SPJ; Fremont DH; Diamond MS
    Immunity; 2021 Oct; 54(10):2399-2416.e6. PubMed ID: 34481543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein.
    He Y; Li J; Li W; Lustigman S; Farzan M; Jiang S
    J Immunol; 2006 May; 176(10):6085-92. PubMed ID: 16670317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antigen-Antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD.
    Fung KM; Lai SJ; Lin TL; Tseng TS
    Front Mol Biosci; 2022; 9():797132. PubMed ID: 35392535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epitope mapping of severe acute respiratory syndrome coronavirus 2 neutralizing receptor binding domain-specific monoclonal antibodies.
    Maghsood F; Amiri MM; Zarnani AH; Salimi V; Kardar GA; Khoshnoodi J; Mobini M; Ahmadi Zare H; Ghaderi A; Jeddi-Tehrani M; Schmidt S; Laumond G; Moog C; Shokri F
    Front Med (Lausanne); 2022; 9():973036. PubMed ID: 36148457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection.
    Guenthoer J; Lilly M; Starr TN; Dadonaite B; Lovendahl KN; Croft JT; Stoddard CI; Chohan V; Ding S; Ruiz F; Kopp MS; Finzi A; Bloom JD; Chu HY; Lee KK; Overbaugh J
    Proc Natl Acad Sci U S A; 2023 Jun; 120(23):e2220948120. PubMed ID: 37253011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants.
    Cho H; Gonzales-Wartz KK; Huang D; Yuan M; Peterson M; Liang J; Beutler N; Torres JL; Cong Y; Postnikova E; Bangaru S; Talana CA; Shi W; Yang ES; Zhang Y; Leung K; Wang L; Peng L; Skinner J; Li S; Wu NC; Liu H; Dacon C; Moyer T; Cohen M; Zhao M; Lee FE; Weinberg RS; Douagi I; Gross R; Schmaljohn C; Pegu A; Mascola JR; Holbrook M; Nemazee D; Rogers TF; Ward AB; Wilson IA; Crompton PD; Tan J
    bioRxiv; 2021 Apr; ():. PubMed ID: 33821267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies.
    Li R; Mor M; Ma B; Clark AE; Alter J; Werbner M; Lee JC; Leibel SL; Carlin AF; Dessau M; Gal-Tanamy M; Croker BA; Xiang Y; Freund NT
    Commun Biol; 2022 Aug; 5(1):789. PubMed ID: 35931732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants.
    Ishimaru H; Nishimura M; Tjan LH; Sutandhio S; Marini MI; Effendi GB; Shigematsu H; Kato K; Hasegawa N; Aoki K; Kurahashi Y; Furukawa K; Shinohara M; Nakamura T; Arii J; Nagano T; Nakamura S; Sano S; Iwata S; Okamura S; Mori Y
    J Virol; 2023 Jun; 97(6):e0028623. PubMed ID: 37191569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.
    Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H
    Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants.
    Ko SH; Chen WY; Su SC; Lin HT; Ke FY; Liang KH; Hsu FF; Kumari M; Fu CY; Wu HC
    J Biomed Sci; 2022 Dec; 29(1):108. PubMed ID: 36550570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibodies constructed from COVID-19 convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and other human coronaviruses.
    Peng Y; Liu Y; Hu Y; Chang F; Wu Q; Yang J; Chen J; Teng S; Zhang J; He R; Wei Y; Bostina M; Luo T; Liu W; Qu X; Li YP
    Front Immunol; 2022; 13():1056272. PubMed ID: 36618428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.